Topics

Fagron to pay $22.5 million to settle U.S. allegations over inflated prices

07:51 EST 7 Nov 2019 | Reuters

Pharmaceutical supplier Fagron Holding USA LLC will pay $22.5 million to resolve allegations that its subsidiaries inflated average wholesale prices for compound drug ingredients and submitted fraudulent claims to federal healthcare programs, the U.S...

Original Article: Fagron to pay $22.5 million to settle U.S. allegations over inflated prices

NEXT ARTICLE

More From BioPortfolio on "Fagron to pay $22.5 million to settle U.S. allegations over inflated prices"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...